Astrazeneca Plc Stock Current Liabilities
| AZNN Stock | MXN 1,367 16.26 1.18% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca |
AstraZeneca PLC Company Current Liabilities Analysis
AstraZeneca PLC's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current AstraZeneca PLC Current Liabilities | 15.93 B |
Most of AstraZeneca PLC's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, AstraZeneca PLC has a Current Liabilities of 15.93 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current liabilities for all Mexico stocks is 101.61% lower than that of the firm.
Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 4.74 T | |||
| Shares Outstanding | 3.1 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 17.94 % | |||
| Price To Earning | 39.41 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 95.42 X | |||
| Revenue | 44.35 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 9.33 B | |||
| Net Income | 3.29 B | |||
| Cash And Equivalents | 15.63 B | |||
| Cash Per Share | 5.96 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 1.90 % | |||
| Current Ratio | 1.23 X | |||
| Book Value Per Share | 11.96 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 19.72 X | |||
| Price To Earnings To Growth | 1.37 X | |||
| Number Of Employees | 48 | |||
| Beta | 0.19 | |||
| Market Capitalization | 4.04 T | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 8.07 B | |||
| Working Capital | (3.16 B) | |||
| Current Asset | 12.77 B | |||
| Current Liabilities | 15.93 B | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 3.52 % | |||
| Net Asset | 96.48 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.